Cogentis Therapeutics
UEI: T5K6EP6DD251
• CAGE: 7FCZ0
Overview
Awardee Type
Parent
Federal Capability Statement
Developing new therapies for Alzheimer's and related dementias.
Keywords
PHARMACEUTICAL, RESEARCH
Headquarters
Columbia, MD
United States
United States
Most Recent Award
Sept. 22, 2021
Calculating
Federal grant recipient
COGENTIS THERAPEUTICS INC
(UEI T5K6EP6DD251, CAGE 7FCZ0)
is headquartered in Columbia MD.
Its primary registered NAICS is 541714 Research and Development in Biotechnology (except Nanobiotechnology).
The corporation
was founded in May 2015 and
federally registered in
August 2015.
Federal Award Analysis
Cogentis Therapeutics federal award history
$-
Contracts
$-
Subcontracts
$-
Grants
$-
Subgrants
$-
Total
No Results
Calculating
Calculating
No Results
Calculating
Calculating
No Results
Calculating
Calculating
| Year | Contracts | Subcontracts | Grants | Subgrants |
|---|
No Results
Calculating
Calculating
No Results
Calculating
Calculating
Federal Registration and Certifications
Legal Name
COGENTIS THERAPEUTICS INC
UEI
T5K6EP6DD251
CAGE Code
7FCZ0
SBA Certifications
None
Self Certifications
Self-Certified Small Disadvantaged Business
Entity Structure
Corporate Entity (Not Tax Exempt)
Purpose of Registration
Federal Contracts and Assistance
Date Founded
May 26, 2015
Initial Registration
Aug. 6, 2015
Last Registration
Oct. 3, 2024
Registration Activation
Oct. 3, 2024
Registration Expiration
Oct. 1, 2025
Fiscal Year End
December 31
Reported Entity Types
For Profit Organization
State of Incorporation
DE
Country of Incorporation
USA
Employees
<500
Accepts Credit Cards
No